A novel agent for the treatment of lung cancer. Researchers have discovered that the anthelmintic drug Rafoxanide has a significant effect in inhibiting the growth, invasion, and migration of non-small cell lung cancer (NSCLC) cells, the most common type of lung cancer
nature.comSubmitted by AlejoRamirezO t3_10bvme7 in science